EIF5A and diabetes mellitus: Previous data from mouse models identified that pharmacological modulation of the hypusination of eIF5A enhanced beta cell mass and improved glucose tolerance in mouse models of both T1D and T2D [14,16], thereby suggesting an important role for eIF5AHyp in the setting of diabetes.